Partnering

Partnerships are a key component of Pathway’s corporate strategy to maximize the potential of its novel PI3K and mTOR inhibitors. Pathway offers a portfolio of differentiated and best in class PI3K and mTOR inhibitors along with significant drug discovery and development expertise. Companies interested in collaborating with Pathway are invited to contact us to discuss our portfolio of programs and/or to discuss how our research & development capabilities might be leveraged to accelerate development of novel therapeutics.

Partnering inquiries may be directed to info@pathwaytx.com